KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $13.1 million.

  • Novavax's Capital Expenditures rose 47.01% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 72.87%. This contributed to the annual value of $13.1 million for FY2024, which is 75.72% down from last year.
  • Novavax's Capital Expenditures amounted to $13.1 million in FY2024, which was down 75.72% from $53.8 million recorded in FY2023.
  • In the past 5 years, Novavax's Capital Expenditures ranged from a high of $89.1 million in FY2022 and a low of $13.1 million during FY2024.
  • For the 3-year period, Novavax's Capital Expenditures averaged around $52.0 million, with its median value being $53.8 million (2023).
  • Per our database at Business Quant, Novavax's Capital Expenditures skyrocketed by 2,833.39% in 2020 and then tumbled by 75.72% in 2024.
  • Novavax's Capital Expenditures (Yearly) stood at $54.5 million in 2020, then increased by 0.05% to $54.5 million in 2021, then soared by 63.40% to $89.1 million in 2022, then slumped by 39.62% to $53.8 million in 2023, then slumped by 75.72% to $13.1 million in 2024.